A new mixed-methods study published in the Journal of Eating Disorders by Josefa Ilg, Anne-Katrin Merz, Lena Kramer, Alexander Nettlau, Anja Hilbert, and Ricarda Schmidt offers one of the most detailed portraits to date of what it actually means to live with ARFID as an adult in the community. Drawing on data from 97 adults with an interview-based diagnosis of ARFID, the research team combined qualitative accounts of personal impairment with quantitative measures of symptoms, temperament, and personality traits, providing an unusually granular view of both the burden of the disorder and the remarkably varied paths it can take over time.

The methodological design was deliberately two-pronged. Participants, recruited through an online study on ARFID, answered open-ended questions asking them to describe in their own words what they struggle with most because of their avoidant or restrictive eating and how their symptoms have changed since onset. The researchers then applied a qualitative content-thematic analysis to these free-text responses, a technique that allows themes to emerge from the data rather than imposing pre-existing categories. In parallel, established questionnaires assessed ARFID symptom severity, obsessive-compulsive personality traits, temperament, and sensory sensitivity, and statistical comparisons were run across groups defined by different symptom trajectories.

What emerged from the thematic analysis was a taxonomy of suffering that extends far beyond the dinner table. Seven main themes of impairment were identified. Health-related impairment was by far the most commonly reported, cited by 68.8 percent of participants, encompassing concerns about nutritional deficiencies, medical consequences, and the physical toll of a restricted diet. Impairment of lifestyle followed at 39.6 percent, capturing restrictions on everyday activities such as travel, dining out, work events, and social gatherings that revolve around food. Notably, 34.4 percent of participants described the eating behavior itself as a burden, pointing to the exhausting, distressing nature of the avoidance and restriction rather than only its downstream consequences.

The social dimension of ARFID proved equally consequential. Nearly a quarter of respondents, 24.0 percent, reported impairment stemming from their social relationships, including negative or dismissive responses from the social environment. Within this broader social theme, 13.5 percent specifically described difficulties in romantic partnerships, where shared meals are a cornerstone of intimacy and everyday routine, and 8.3 percent described challenges in family life and parenthood, including worries about modeling eating behavior for children or navigating mealtimes as a parent with a severely restricted diet. Perhaps most sobering for the healthcare system, 2.1 percent of participants reported impairment directly attributable to their experiences with practitioners, suggesting that even clinical encounters can become a source of burden for adults whose disorder is frequently misunderstood or overlooked.

Equally significant were the findings on symptom progression. Rather than following a single course, ARFID in this community sample displayed striking heterogeneity, falling into four distinct trajectory groups. The largest group, 41.3 percent of participants, reported improved symptoms over time. A further 32.6 percent described consistent symptoms that neither improved nor worsened, 18.5 percent reported worsened symptoms, and 7.6 percent described a varying course marked by fluctuations. For a disorder often assumed to be either a transient phase of childhood or a lifelong fixed condition, this variability is a finding with real clinical weight.

The quantitative comparisons between progression groups sharpened the picture. Adults whose symptoms had improved were older and more highly educated than those whose symptoms had deteriorated, suggesting that age and educational attainment may serve as markers, or perhaps even enablers, of recovery or adaptation. Conversely, greater fear of aversive consequences, one of the three core maintaining mechanisms of ARFID alongside sensory sensitivity and low interest in eating, was associated with a deteriorated course. This aligns with the mechanistic model of ARFID as a disorder maintained by negative reinforcement: individuals who dread choking, vomiting, or other frightening consequences of eating may progressively narrow their food repertoire, entrenching the restriction and its consequences in a self-perpetuating loop. The association between worsening symptoms and this specific fear profile offers a potential target for early identification and intervention.

The study’s authors are careful to frame these findings as exploratory. Because the data are cross-sectional and retrospective, based on participants’ own accounts of how their symptoms have changed, they cannot establish causality or prospectively track the disorder’s course. Higher education and age might correlate with improvement for reasons ranging from greater access to information and healthcare to cognitive resources for developing coping strategies, and the fear-of-aversive-consequences association could reflect either a driver of deterioration or a feature of more entrenched cases. The researchers explicitly call for longitudinal studies that can prospectively identify the risk and protective factors governing ARFID’s progression and persistence across adulthood.

Even so, the implications of the work are considerable. For clinicians, the seven impairment themes provide a practical map of the domains worth assessing and addressing in adult patients, from medical monitoring and nutritional rehabilitation to couple and family counseling and even the quality of the therapeutic encounter itself. The finding that nearly four in ten participants reported lifestyle-wide restrictions underscores that ARFID in adulthood is not a quirk of picky eating but a condition with pervasive functional impact. The public health significance is equally clear: if a substantial fraction of adults with ARFID report worsening symptoms while the majority remain stable or improve, then understanding what distinguishes these trajectories could redirect scarce treatment resources toward those most at risk.

The study also carries a message for primary care and mental health services, where adult ARFID frequently goes unrecognized precisely because screening and awareness are calibrated to childhood presentations and to better-known eating disorders such as anorexia nervosa and bulimia nervosa. Adults whose restrictive eating is driven by sensory aversion or fear rather than body image concerns may never see themselves reflected in standard eating disorder screening, and their reports of practitioner-related burden in this study hint at the cost of that invisibility. By centering the lived experience of adults with interview-confirmed diagnoses, the Leipzig-based research team has produced evidence that ARFID is a genuine adult mental health concern, one whose heterogeneous course demands the same longitudinal scientific scrutiny long afforded to other eating disorders.

Beyond its headline findings, the study illustrates the value of mixed-methods designs in eating disorder research, where standardized symptom scores alone can miss the texture of daily struggle. By pairing closed-ended questionnaire data with open-ended narratives, the researchers allowed participants to name burdens that might otherwise never appear in clinical inventories, such as the strain of explaining one’s eating at work functions or the anxiety of feeding children while maintaining a narrow diet oneself. This approach is particularly suited to ARFID, a diagnosis whose presentation varies widely depending on which of its maintaining mechanisms dominates in a given individual.

The community-based recruitment also matters scientifically. Much of the existing ARFID literature draws on treatment-seeking samples, which risk overrepresenting severe or medically complicated cases and underrepresenting adults who have never been diagnosed. By studying individuals in the general population with interview-confirmed diagnoses, the Leipzig team captured a broader spectrum of severity, including people who may have developed informal coping strategies over years of living with the condition. This may partly explain why the largest trajectory group reported improvement rather than deterioration, a pattern that could look different in clinical cohorts.

The measurement of obsessive-compulsive personality traits, temperament, and sensory sensitivity alongside symptom severity reflects the growing recognition that ARFID sits at the intersection of eating pathology and broader neurodevelopmental and personality characteristics. Elevated sensory sensitivity, for instance, is frequently reported in ARFID and overlaps with profiles seen in autism spectrum conditions, while perfectionism and rigidity may sustain restriction through inflexible food rules. Including these constructs in a single adult sample helps lay groundwork for identifying which psychological profiles predict which courses, an essential step toward personalized intervention.

Practically, the trajectory findings suggest that clinicians should not assume stability in adult ARFID. A substantial minority of participants described worsening symptoms, and the association with heightened fear of aversive consequences points to a specific, assessable risk marker that could be screened for during routine evaluation. Conversely, the link between improvement and higher age or education hints that accumulated life experience, resources, or self-directed learning about the condition may support adaptation, hypotheses that future longitudinal work can test directly.

As an open-access publication supported by Leipzig University’s Behavioral Medicine Research Unit, the study also lowers barriers for clinicians and researchers worldwide to build on its findings, an important consideration for a disorder whose adult presentation remains under-recognized across healthcare systems.

Subject of Research: Adult community-dwelling individuals with avoidant/restrictive food intake disorder (ARFID), examining their experienced impairments and symptom progression patterns

Article Title: Avoidant/Restrictive food intake disorder in adults within the community: A mixed-method study on individual impairment and progression

Article References: Ilg, J., Merz, A.-K., Kramer, L., Nettlau, A., Hilbert, A., & Schmidt, R. (2026). Avoidant/Restrictive food intake disorder in adults within the community: A mixed-method study on individual impairment and progression. Journal of Eating Disorders, 14(1), Article 218. https://doi.org/10.1186/s40337-026-01765-w

Image Credits: AI Generated

DOI: 10.1186/s40337-026-01765-w

Keywords: ARFID, avoidant/restrictive food intake disorder, eating disorders, adult mental health, impairment, symptom progression, mixed-methods research, sensory sensitivity, lived experience, psychopathology, Journal of Eating Disorders, longitudinal research

Fetal alcohol spectrum disorders are a group of lifelong neurodevelopmental conditions caused by alcohol exposure during pregnancy. The spectrum encompasses three subtypes: fetal alcohol syndrome (FAS), in which growth retardation and characteristic craniofacial features such as a narrow upper lip, a smoothed philtrum, and shortened palpebral fissures are fully present; partial fetal alcohol syndrome (pFAS), where these physical markers appear only incompletely; and alcohol-related neurodevelopmental disorder (ARND), in which the physical signs are absent but the neurocognitive damage remains. Across all subtypes, the core injury involves the brain. Affected individuals commonly experience impairments in executive function, intelligence, attention, learning, memory, impulse control, self-regulation, and social cognition. Global prevalence estimates vary widely, from 0.2 to 25 percent depending on region, with the highest rates in Europe and South Africa; in Germany, an estimated one to two people per 100 live with FASD. Despite being described in the scientific literature since the late 1960s, the condition is still widely under-recognized, particularly in adults, in whom the facial features tend to become less distinctive over time while psychiatric symptoms persist or even worsen.

The new study set out to address a persistent weakness in the existing literature: most previous estimates of psychiatric comorbidity in adults with FASD rest on very small or highly selective samples. A landmark 1998 study included only 25 participants and found that 92 percent met criteria for at least one DSM-IV Axis I disorder, with 48 percent also diagnosed with a personality disorder. A widely cited meta-analysis by Popova and colleagues reported a pooled prevalence of 54.5 percent for alcohol or drug use disorders among people with FASD, with alcohol use disorders four times and illicit drug-related disorders 21 times more common than in the general US population. A Swedish registry study of 79 adoptees from Eastern Europe found psychiatric hospitalization rates of 33 percent, compared with 5 percent in the general Swedish population. Yet these figures derive from convenience samples, orphan cohorts, or small clinical series, and almost none came from German-speaking countries. Larger, systematically assessed samples, and in particular gender-separated analyses, had been lacking.

The Essen team recruited 238 adults, 51.3 percent of them women and 48.7 percent men, who attended the hospital’s specialized FASD diagnostic service, established in 2018 in a German metropolitan area. The mean age was 28 years and the mean global IQ was 74, close to the range of mild intellectual disability. Among the diagnoses, 46.6 percent of participants had FAS, 38.7 percent had pFAS, and 14.7 percent had ARND. Because Germany has no evidence-based adult-specific diagnostic guideline, the researchers applied the German S3 guideline for children and adolescents together with a national expert consensus adapted for adults. Prenatal alcohol exposure, facial morphology, growth retardation, and multiple neurocognitive domains, including global intelligence, attention, memory, planning, and executive functioning, were measured with standardized assessments across two appointments of roughly two to three hours each.

Crucially, psychiatric comorbidity was not inferred from records or questionnaires. The researchers administered the DIPS Open Access, a structured clinical interview based on DSM-5 criteria that is comparable to the internationally used SCID-5 and has been repeatedly validated in German-speaking outpatient, inpatient, and research populations. This diagnostic rigor matters, because structured interviews substantially reduce the over- and under-reporting that can distort prevalence estimates in vulnerable populations with cognitive impairments. Categorical variables were compared between women and men using chi-square tests, or Fisher’s exact test where expected cell counts fell below five.

The results paint a picture of considerable psychological suffering. Overall, 31 percent of men and 41 percent of women met criteria for at least one comorbid mental health disorder, compared with a 12-month prevalence of 27 percent in the general German population. Anxiety disorders were the most common, affecting 13.8 percent of men and 13.1 percent of women, followed by major depression at 7.8 percent in men and 9.8 percent in women. Post-traumatic stress disorder was diagnosed in 4.1 percent of women, higher than the 2.3 percent reported for the general German population. Notably, the expected gender gap in overall psychiatric morbidity largely disappeared in this sample: women and men with FASD were affected at similar rates, a pattern that diverges from the well-replicated general-population finding that women experience more depression and anxiety while men show more substance problems.

The suicidality data are the study’s most alarming finding. Lifetime suicide attempts were reported by 32.8 percent of women and 17.2 percent of men, rates that dwarf general-population lifetime estimates of between 0.4 and 5.1 percent in Germany and the United States. The figures are consistent with earlier smaller studies and with data showing that completed suicide is a leading cause of death in FAS, with one large Canadian study reporting that 15 percent of people with FAS died by suicide. The researchers point to an accumulation of risk factors: the cognitive and daily-life impairments that come with FASD, financial hardship, low social support, heightened impulsivity, and frequent histories of trauma. The higher rate among women mirrors patterns seen in general psychiatric research, potentially reflecting greater exposure to victimization and traumatization. The authors argue that caregivers and professionals working with people with FASD should routinely assess suicidality and establish easy-to-use emergency strategies for individuals at acute risk.

Substance use presented a more nuanced picture. Thirty-day alcohol use was reported by 49.1 percent of men and 36.1 percent of women, actually below the rates in the general German population, where 74.8 percent of men and 66 percent of women had drunk alcohol in the preceding 30 days. More strikingly, 9.5 percent of men and 13.1 percent of women in the FASD sample had never consumed alcohol in their lives, a higher proportion of lifetime abstinence than in the general population. Cannabis told a different story: 30.2 percent of men and 17.2 percent of women reported use in the past 12 months, well above the general-population figures of 10.7 percent for men and 6.8 percent for women, and above even the young adult age groups. The researchers speculate that some individuals may use cannabis to self-medicate symptoms shared with ADHD, such as impulsivity and hyperactivity, or to regulate sleep problems, which are common in FASD. This self-treatment could be particularly harmful, since both acute and chronic cannabis use impair learning, memory, and attention, the very functions already compromised by prenatal alcohol exposure, potentially accelerating functional decline.

Formal substance use disorders, however, were far rarer in this sample than the literature had suggested: alcohol use disorders were diagnosed in 2.6 percent of men and 0.8 percent of women, and cannabis use disorders in 1.7 percent of men and 0.8 percent of women, against earlier reports ranging from 9 percent to over 50 percent. The authors caution that the small absolute numbers limit firm conclusions, and that selection effects may cut in both directions. People with severe comorbid illness or low social support may never reach a specialized diagnostic center at all, given that such services are scarce in Germany, involve long waiting times, and often require travel and caregiver accompaniment. The true psychiatric burden among all adults with FASD could therefore be even higher than measured, and the absence of a quantified ADHD comorbidity assessment, deliberately omitted to spare patients a five-appointment diagnostic procedure, leaves open the possibility of confounding, since roughly half of children with FASD also meet criteria for ADHD, which itself elevates risks of psychiatric illness, substance use, and suicidal behavior.

For the researchers, the message is clear. Adults with FASD are not simply living with a neurodevelopmental condition; they are carrying a compounded burden of anxiety, depression, trauma, and suicidal risk that current care systems are ill-equipped to address. Greater awareness of FASD within mainstream psychiatric services could turn comorbid presentations into diagnostic opportunities, while treatment planning must account for the learning, memory, and attention deficits that can undermine standard therapeutic approaches. The study’s authors call for specialized treatment that targets not only FASD-specific symptoms but also the comorbid conditions that, untreated, may shorten lives. With prevention programs such as the German health-insurance-approved “Stress-Stop” intervention already available, the infrastructure for better care exists in embryo; what is needed now, the researchers argue, is the clinical and political will to scale it.